Abingworth Bioventures

Overview

Abingworth Bioventures is a prominent transatlantic life sciences investment firm dedicated to transforming cutting-edge science into novel medicines. With over $2 billion under management, the firm has invested in more than 185 life science companies since its inception in 1973, leading to 49 mergers and acquisitions and 75 initial public offerings. Abingworth's investment strategy encompasses seed and early-stage ventures, development-stage companies, and clinical co-development opportunities, providing capital and expertise to top-tier management teams building world-class companies. The firm's investment approach is characterized by a commitment to innovation and a deep understanding of the life sciences sector. Abingworth's team of experienced professionals operates from offices in London, Menlo Park (California), and Boston, enabling the firm to effectively support its portfolio companies across key biotech hubs in both the United States and Europe. This transatlantic presence allows Abingworth to tap into deep talent pools and scientific networks, fostering productive interactions with entrepreneurs and facilitating access to high-quality deal flow. Abingworth's track record includes successful investments in companies such as Alnylam Pharmaceuticals, Gilead Sciences, and IDEC Pharmaceuticals. The firm's philosophy centers on providing patient capital and strategic guidance to accelerate the development of innovative therapeutics. By leveraging its extensive experience and global network, Abingworth continues to play a pivotal role in advancing the life sciences industry, aiming to bring transformative medicines to patients worldwide.

Investment Focus

• Innovative therapeutics with potential to significantly improve human health
• Experienced management teams
• Companies at seed, early, or development stages
• Opportunities in biotechnology, pharmaceuticals, medical devices, and related sectors

Portfolio Companies